Vikas Mehta

Platforms are in, point solutions are out as the healthcare AI category leaders come into focus this year. In conversation with Shelby Livingston at Endpoints News, I shared: 1. Why AI-first companies have the greatest platform potential and heuristics for identifying these opportunities at the earliest stages, 2. How companies are differentiating through co-development and distribution partnerships with leading healthcare institutions, and 3. Strategies for navigating anemic budgets and constrained market sizes through business model innovation such as AI-enabled services and pay for performance models Read more here: https://lnkd.in/dJWqv_zC Bessemer Venture Partners Abridge #healthcare #lifesciences #AI #generativeAI

248

13 Comments

A little late, even though this process started in July.... Excited to share our latest investment in Heads Together Health!! We met Steve DeVrieze in October last year, and we think they are poised for impressive growth! Read more here: https://lnkd.in/ecYcqqkn #earlystagestartup #earlystageinvesting #VCinvestment #ncstartups #nctechstartups

18

Aon published a study this week showing that a Fortune 500 Lyra Health customer saved more than $3 in health care costs for every $1 they spent on Lyra. This is a staggering return on investment. Lyra can deliver the highest value in mental health care because it delivers the best outcomes in the field, having tirelessly invested time and expertise in creating the best care available. This blog is a follow-up from the one I wrote a couple months ago showing that Lyra can also prove sustained savings over four years. Proud of our team for all that they do to help those in need and proving that what’s best for people can also be best for business’ bottom lines. https://bit.ly/4fopHoX 

168

💡Benchmarks in the investment industry serve as a standard for measuring the performance of securities, mutual funds, or investment managers. They provide a reference point for analyzing allocation, risk, and return of a portfolio, enabling investors to make informed decisions. Thanks Peter Walker for keeping us all informed!! Can’t wait for this!! Follow and get on the waitlist for this one! #benchmarks #fundraising #Capitalraise #founders #womenshealth #femhealth #medtech #wellness

16

Join us tomorrow for a panel discussion on the complex relationship many FirstGens have to money and how that affects founders, investors, operators and others. See you tomorrow! https://lu.ma/9rixyzgs

23

2 Comments

Anne Wojcicki, CEO of 23andMe, has announced plans to take the genetic testing company private. This strategic move aims to provide more flexibility in navigating regulatory challenges and to accelerate growth opportunities. The decision follows a trend of health tech companies seeking private ownership to focus on long-term objectives. Wojcicki highlighted the importance of this shift to maintain the company's commitment to innovation and customer-centric services. Taking 23andMe private reflects a bold step towards enhancing its position in the rapidly evolving genomics industry. Read more about this exciting development here: https://lnkd.in/gdrC3a64 #genomics #IPO #privatisation #23andMe

13

One of my proudest moments as an investor occurred today as Alaffia Health announced its series A because it shows how the Aperture® Venture Capital vision of multi-level, multi-generational #impactinvesting is succeeding in the marketplace. Here’s the model in its most basic form : ✅As diverse fund managers with meaningful capital to allocate, we are changing the VC landscape every day just by doing our day jobs. ✅As Black/Brown investors with ~40 years experience collectively, Aperture GPs have access to talent /excellence that others do not, so our portfolio *organically* is more inclusive by race, gender and geography even while optimizing for financial outcomes (all about the alpha). ✅Our most successful portco’s are using financial #innovation to solve market problems that impact underrepresented demographics and underserved communities. Alaffia Health is a shining example of the impact portion of our overall fund thesis, and we couldn’t be prouder of TJ Ademiluyi and Adun Akanni, MPH, PMP - the dynamic brother-sister founder duo whose vision we have steadfastly supported on their journey. Congratulations to TJ and Adun from William Crowder and myself, as well as the whole Aperture team- Marjorie King Philip McKenzie Yves Louis-Jacques Tanvi Lal Michelle Dhansinghani Lisha Bell Katie Kelly Amy Chung Cindy Chong, CFA Brian Fernandes-Halloran Monroe France Jayden Pantel Darren Herman Evan Wladis Neal Triplett Thomas Scriven Peter Ammon Irina Bit-Babik Tim Milanich Rob Rahbari

38

18 Comments

Sometimes, the best way to describe what Caresyntax does is through real results. We don't just talk about optimizing healthcare – we deliver. This case study dives deep into how we partnered with a Southeastern health system to optimize their complex ventral hernia repair program. The results are staggering: - Annual cost reduction of $700,000 - Service line net margin improvement of $15,000 per patient - 54% decrease in post-surgical opioid use (safer, happier patients) - 33% reduction in length of stay (patients recover faster) Here's the secret sauce: We go beyond traditional data analysis. Our unique approach connects all the dots – patient factors, treatment details, costs, and reimbursements. This allows us to identify hidden opportunities for improvement. Read this case study to see how we did it. https://lnkd.in/gtebkRU7 #DataDrivenSurgery

88

4 Comments

Abby Levy talks about venture's role in US healthcare and what we can expect to see as technology impacts the space on TFR. Check out the rest of the conversation with Abby & Alan Patricof of Primetime Partners on Episode 433.

34

6 Comments

As I said right at the start of this week's The Heart of Healthcare Podcast, Shivdev Rao is one of the most exceptional founders I have ever worked with. He is also a great human being. In this week's episode he shares what is it like leading the 🚀 that is Abridge and some awesome life lessons. IMHO this is a great listen for founders building in both the AI and healthcare fields!

57

3 Comments

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

3

3 Comments

Since early 2021, VC quarterly exit values have plummeted to $50B or below, a stark contrast to the six consecutive quarters of $100B+ exits before then. With IPOs dwindling and M&A activity slow, the future of venture industry exits appears uncertain. Will we see a surge in private venture-backed company acquisitions? This could be a crucial and innovative strategy to boost VC exits. Increased private acquisitions might offer a much-needed lifeline, providing a creative solution to the current exit drought in the venture capital market. #venturecapital #inspireglobalventures

3

PE - PE Acceleration Toolkit (i.e. not Playbook) What commercial, GTM and growth areas do you cover in your "PE Portfolio Company Toolkit" (i.e. some funds like Vista Equity Partners call it a Playbook but I refer to it as toolkit with the aim of it being a participatory, not a prescriptive playbook)? Some ideas* come to mind - what else? (* i.e. Commercial/GTM/Revenue Growth - not including Product, Engineering, R&D and other functions) 1. Sales Optimization   - Sales Org Structure   - Sales Management Process   - Sales Prospecting & Outbound   - Sales Process Engineering - Pipeline Management - Forecasting & Commit Process - Forecasting Rollups - CEO & Board   - Sales performance metrics and KPIs   - Channel Sales, Partner and alliance programs   - Rev Ops & Sales Enablement   - Sales Quota, Compensation & Incentives   - Sales Tech & Automation 2. Marketing Optimization   - B2B Demand Generation strategy   - Marketing Management - Marketing Process Engineering - Defining Lead Nomenclature - Campaign Management - Strategic Messaging Architecture   - PLG - Product Led Growth   - Digital & Inbound marketing    - Account-based marketing (ABM) - Customer Marketing - Product Marketing - Marketing/Sales Alignment & SLAs   - Marketing Metrics / KPIs   - Marketing Tech & Automation 3. Customer Management, Success and Retention   - Customer onboarding processes   - VOC - collecting and analyzing customer feedback   - Customer Segmentation   - Customer Management Processes   - Proactive customer Engagement   - AM & Expansion Sales   - Renewal strategies   - Customer loyalty strategies   - Customer support optimization   - Customer metrics and KPIs 4. Pricing and Packaging   - Pricing strategies   - Value-based pricing   - Discounting strategies & pricing transparency   - Subscription and usage-based models   - Pricing experimentation and A/B testing   - Competitive pricing analysis 5. Operational Efficiency   - SaaS metrics (CAC, LTV, churn rate, etc.)   - Process automation and workflow optimization 6. Talent & Culture   - Leadership & Management    - Attracting and retaining top talent   - Building a high-performance culture   - Performance Management   - Remote work best practices   - Continuous learning and development 7. Community Building   - Community creation & engagement   - Building an ecosystem around the product   - Customer Advocacy Programs 8. Data and Analytics   - Data-driven decision-making   - Business intelligence (BI) tools and dashboards   - Data governance, security and privacy   - AI applications Other: 9. Product (& GTM Alignment) 10. M&A (Commercial/GTM integration) 11. Finance (Supporting the GTM org) 12. GTM Board Updates & KPIs 13. Etc. ------------------ #pe #privateequity #business

82

13 Comments

According to the latest report from Rock Health, digital health funding in Q1 2024 totaled $2.7B across 133 deals, with an average deal size of $20.6M. It doesn’t break out device-related investments, but most medtech founders I meet these days are being forced to chase tiny rounds made up of endless little checks, consuming valuable energy and slowing their progress. The benign neglect of this next generation of diagnostic and therapeutic devices is counterproductive and surprising. Given the crowded virtual care market, for example, I’d expect more such companies would be exploring medtech partnerships, investments or acquisitions that'd enable them to back integrate into delivering sharper, and more differentiated, care and treatment. This is exactly what Maverix Medical is doing from the other direction: Reshaping the entire spectrum of lung cancer care by integrating more advanced + effective approaches to screening and diagnosis, treatment and therapeutics, and even palliative care…And putting it all to work through an innovative provider network. One notable investor exception is Y Combinator partner Surbhi Sarna who’s been backing great teams like Selera Medical (YC W24) doing foundational work on ambitious medical devices. Without more support from investors like her, we’re going to increasingly find ourselves stuck with the incremental portfolio improvements from the incumbents, and that’s just not nearly enough.

58

5 Comments

https://lnkd.in/gZeefZhX Private equity funds gathered $176.7 billion in the first quarter of 2024, a drop of roughly 10 percent from the $195.5 billion recorded in the same period last year, according to preliminary findings from PEI data. Interest rate uncertainty continues to weigh on buyout and exit activity, while record dry powder for the asset class remains stacked for 2024, the data found.

2

Imagine swallowing the competition whole. That's what many players in tech do via roll-up strategies, gobbling up smaller firms to deliver richer solutions and amass greater market share. Where else are roll-up strategies common? // HEALTHCARE Picture being a patient at a medical practice that’s been part of a roll-up in Healthcare Services. It's an industry ripe for roll-ups due to its fragmented nature and potential for greater efficiency. // CONSUMER SERVICES Or let's say you needed your HVAC serviced, and notice your local repairman is now part of a bigger Consumer Services entity? Centralized management and scale economy turn these localized businesses into roll-up targets. // FINANCIAL SERVICES Think about your insurance agent or wealth management advisor. They're working in complex, highly regulated environments. In the Financial Services sector, roll-ups offer an effective way to consolidate expertise, streamline operations, and enhance customer offerings. // MANUFACTURING Now, imagine driving past factories under a new name — the result of Manufacturing and Industrial Services roll-ups. Bulk purchasing reduces costs, enhances production capabilities, and expands geographical footprints. // REAL ESTATE Lastly, envision your real estate brokerage firm. The industry sees roll-ups as a strategic move to increase market penetration, enhance service offerings, and hike up portfolio value. Roll-ups play a huge role in most industries, rather like a snowball rolling downhill, gaining momentum, and size. Are you seeing roll-ups in your sector or considering M&A?

11

1 Comment

Is private equity owned healthcare a positive or a negative in regard to real health outcomes for patients? I asked Ambar Bhattacharyya of Maverick Ventures this question and more on Episode 438 of The Full Ratchet. Tune into the show to catch our discussion.

13

1 Comment

Open-source models can be a strong lever for increasing gross margins at AI companies, especially those that have hefty cost structures (e.g., enterprise sales orgs that require significant customer success or implementation resources, as well forward-deployed AI services models common in healthcare and life sciences). One of many reasons to maintain a modular and flexible stack with minimal dependencies when building an AI company. More on the importance of flexibility in the AI stack: https://lnkd.in/eA2XATRk h/t Delip Rao #ai #artificialintelligence #generativeai #healthcare

51

6 Comments